Alterity Therapeutics Limited
PRNAF
$0.0101
$0.0065180.56%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -2.75% | -22.92% | |||
| Total Revenue | -2.75% | -22.92% | |||
| Cost of Revenue | -2.82% | -44.96% | |||
| Gross Profit | -2.75% | -21.64% | |||
| SG&A Expenses | -2.75% | 24.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -2.65% | 3,680.00% | |||
| Total Operating Expenses | -2.75% | -38.41% | |||
| Operating Income | 2.75% | 40.94% | |||
| Income Before Tax | 2.75% | 41.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.75% | 42.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | 42.19% | |||
| EBIT | 2.75% | 40.94% | |||
| EBITDA | 2.75% | 40.99% | |||
| EPS Basic | 20.00% | 44.44% | |||
| Normalized Basic EPS | 0.00% | 40.00% | |||
| EPS Diluted | 0.00% | 44.44% | |||
| Normalized Diluted EPS | 0.00% | 40.00% | |||
| Average Basic Shares Outstanding | 0.00% | 10.82% | |||
| Average Diluted Shares Outstanding | 0.00% | 10.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
